A Pan-Dengue Virus Immunotherapeutic for Prevention and Treatment

用于预防和治疗的泛登革热病毒免疫疗法

• 批准号: 7940773
• 负责人: L Syd Johnson
• 金额: $ 101.87万
• 依托单位: MACROGENICS, INC.
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-06-17 至 2014-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7940773
• 关键词: Address; Aedes; Affinity; Antibodies; Antibody-Dependent Enhancement; Area; Binding; Binding Sites; Categories; Cell Line; Characteristics; Clinic; Clinical; Clinical Research; Collaborations; Collection; Communicable Diseases; Complement; Culicidae; Cyclic GMP; Dengue; Dengue Hemorrhagic Fever; Dengue Shock Syndrome; Dengue Virus; Development; Diamond; Disease; Drug Formulations; Drug Kinetics; E protein; Engineering; Epitopes; Escape Mutant; Fc Receptor; Fever; Funding; Generations; Goals; Half-Life; Human; Immunization; Immunotherapeutic agent; In Vitro; Individual; Infection; Laboratories; Licensing; Life; Location; Manufactured Materials; Measures; Military Personnel; Modeling; Mus; National Institute of Allergy and Infectious Disease; Outcome; Pharmaceutical Preparations; Phase II Clinical Trials; Population; Prevention; Process; Property; Prophylactic treatment; Proteins; Recording of previous events; Recruitment Activity; Relative (related person); Research; Risk; Serotyping; Serum; Supportive care; Testing; Therapeutic; Therapeutic Agents; Therapeutic Human Experimentation; Therapeutic Monoclonal Antibodies; Time; Tissues; Toxicology; Travel; Validation; Variant; Viral; Virion; Virus Diseases; West Nile virus; Work; antibody engineering; antigen binding; base; cell bank; cellular targeting; cross immunity; cross reactivity; experience; humanized monoclonal antibodies; in vitro testing; in vivo; manufacturing process development; monocyte; neutralizing antibody; neutralizing monoclonal antibodies; nonhuman primate; pathogen; pre-clinical; preclinical study; prevent; product development; prophylactic; receptor; receptor binding; vector mosquito

DESCRIPTION (provided by applicant): The ultimate goal of this project is to develop a licensed immunotherapeutic to prevent and treat the spectrum of febrile illnesses caused by Dengue virus (DV) infection. The work proposed here will result in the validation of product candidates with proven efficacy in vivo, development of manufacturing process and completion of all IND-enabling studies, significantly advancing this product candidate toward clinical use. Individuals infected a second time by DV generally experience more severe disease resulting from poorly neutralizing antibodies from the primary infection leading to an antibody-dependent enhancement (ADE) of infection by recruiting DV particles to monocytes, their primary cellular targets of infection, via Fc??receptors. The immunotherapeutic that we propose will be engineered to eliminate Fc?R binding, and therefore ADE, while maintaining long serum half-life and the ability to bind complement that enhances therapeutic activity. The work will progress through 4 Specific Aims. (1) Engineer a potent, long half-life immunotherapeutic cocktail that neutralizes all four DV serotypes and minimizes selection for escape mutants, while preventing antibody dependent enhancement (ADE) of infection. Existing potent serotype specific MAbs will be used as the basis to build multivalent, multispecific antibody like molecules (IgDARTs) that have many of the desirable therapeutic properties of antibodies and are easily expressed and purified. For diseases with multiple targets, IgDARTs allow generation of simpler cocktails with fewer components than if MAbs were employed. In the case of DV, 4 serotypes will be neutralized by two IgDART molecules. A cross- reactive MAb will also be engineered to serve as an important final component of the drug cocktail to control emergence of escape mutants. Activities will include humanization, affinity maturation to increase potency, de-immunization, and generation of IgDARTs. (2) Perform in vivo studies in mice to establish parameters of prophylactic, therapeutic, and pharmacokinetic activity, as well as measuring the ability to control emergence of escape mutants. (3) Product development and manufacturing. Optimized expression, purification, and formulation conditions will be established for each molecule (2 IgDARTs and 1 MAb). Cell banks will be established for the generation of material suitable for human use that will be manufactured under cGMP conditions. (4) Complete IND-enabling studies. Efficacy, toxicology, and pharmacokinetics will be evaluated in non-human primate models. Human and non-human primate tissue cross-reactivity studies will be performed. Required studies will be performed under GLP conditions. This project aims to advance a collection of DV-neutralizing MAbs into a concise well-defined immunotherapeutic validated for initiation of clinical studies.

描述（由申请人提供）：该项目的最终目标是开发一种获得许可的免疫疗法，以预防和治疗由登革热病毒（DV）感染引起的一系列发热性疾病。这里提出的工作将导致候选产品的体内有效性验证，制造工艺的开发和所有ind支持研究的完成，显着推进该候选产品的临床应用。第二次感染DV的个体通常会经历更严重的疾病，这是由于初次感染的抗体中和不良，导致感染的抗体依赖性增强（ADE），通过Fc受体将DV颗粒募集到单核细胞（其感染的主要细胞靶点）。我们提出的免疫疗法将被设计用来消除Fc？R结合，因此ADE，同时保持较长的血清半衰期和结合补体的能力，从而增强治疗活性。这项工作将通过4个具体目标进行。(1)设计一种有效的、长半衰期的免疫治疗鸡尾酒，可以中和所有四种DV血清型，最大限度地减少对逃逸突变体的选择，同时防止抗体依赖性增强（ADE）感染。现有的高效血清型特异性单克隆抗体将被用作构建多价、多特异性抗体样分子（igdart）的基础，这些抗体具有许多抗体所需的治疗特性，并且易于表达和纯化。对于具有多个靶点的疾病，igdart可以产生比单克隆抗体更简单的混合物，其成分更少。在DV的情况下，4种血清型将被两个IgDART分子中和。一种交叉反应的单抗也将被设计成药物混合物的一个重要的最终组成部分，以控制逃逸突变体的出现。活动将包括人源化、亲和成熟以提高效力、去免疫和生成igdart。(2)在小鼠体内进行研究，建立预防、治疗和药代动力学活性参数，并测量控制逃逸突变体出现的能力。(3)产品开发与制造。每个分子（2个IgDARTs和1个MAb）将建立优化的表达、纯化和配方条件。将建立细胞库，用于生成适合人类使用的材料，这些材料将在cGMP条件下生产。(4)完成ind启用研究。药效、毒理学和药代动力学将在非人类灵长类动物模型中进行评估。将进行人类和非人类灵长类动物组织的交叉反应性研究。所需的研究将在GLP条件下进行。该项目旨在推进dv中和单克隆抗体的收集，使其成为一种简明明确的免疫治疗药物，可用于临床研究的启动。